申请人:Takeda Pharmaceutical Company Limited
公开号:US20160185801A1
公开(公告)日:2016-06-30
The present invention provides compounds of the formula:
that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
本发明提供的化合物具有以下公式:
这些化合物是5HT3受体拮抗剂,因此可用于治疗可通过抑制5HT3受体治疗的疾病,例如呕吐、疼痛、药物成瘾、神经退行性和精神障碍以及胃肠道疾病。还提供了包含这些化合物的制药组合物和制备这些化合物的方法。